Tuesday, Jan. 7th Office Closures & Changes
The Laurel Endoscopy Center 7350 Van Dusen Rd, Suite 230, Laurel, MD 20707 will be closed. Appointments will be rescheduled.
All appointments at Laurel Doctors' Office 7350 Van Dusen Road, Suite 410, Laurel, MD 20707 will be converted to telehealth
All appointments at Columbia Doctors' Office 5500 Knoll North Drive, Suite 460, Columbia, MD 21045 will be converted to telehealth
All appointments at Rockville Doctors' Office Shady Grove Rd. 15001 Shady Grove Road, Suite 300, Rockville, MD 20850 will be converted to telehealth
All appointments at Germantown Doctors' Office 20528 Boland Farm Road, Suite 201, Germantown, MD 20876 will be converted to telehealth
All appointments at Olney Doctors' Office 3415 Olandwood Court, Suite 101, Olney, MD 20832 will be converted to telehealth
All appointments at Silver Spring Doctors' Office 10801 Lockwood Drive, Suite 200, Silver Spring, MD 20901 will be converted to telehealth
Chevy Chase Doctors' Office 5550 Friendship Boulevard, Suite T-90, Chevy Chase, MD 20815 will open at 9:30 a.m.
Washington, D.C. Doctors' Office 2000 Pennsylvania Avenue NW, Suite 3010, Washington, D.C. 20006 will open at 9:30 a.m.
North Bethesda Doctors' Office 6100 Executive Boulevard, Suite 301, North Bethesda, MD 20852 will open at 9:30 a.m.
National Harbor Doctors’ Office 125 Potomac Passage, Suite 250, National Harbor, MD 20745 will open at 9:30 a.m.
Chevy Chase Clinical Research
Clinical Trials
Chevy Chase Clinical Research is the largest program of its kind in the region. Founded in 1996 as part of Affiliated Research Centers, it now operates as an independent research site in partnership with Capital Digestive Care. Over 300 studies have been conducted, covering a wide range of gastroenterology and select areas of internal medicine. Below is a summary of our active clinical trials.
Current Clinical Trials
If you are interested in participating in a clinical trial please contact our office at research@capitaldigestivecare.com or (301) 652-5520.
Clostridium Difficile
This study is for patients 18 years of age or older who currently test positive for Clostridium difficile, better known as C. Diff. The study is 27-weeks, which is designed to evaluate the safety, tolerability, and efficacy of study medication in reduction of recurrence of C-difficile Infection (CDI) in Adults who have received antibacterial drug treatment for recurrent CDI. There is also an additional 27-week extension option for this protocol.
Diabetic Gastroparesis
This study is for patients 18 years of age or older who have been diagnosed with Diabetic Gastroparesis.There is also a continuation and long-term extension study option for this protocol.
Crohn’s Disease
We have multiple studies for Crohn’s diseasefor patients between the ages of 18-75 years old. The potential patient needs to have moderate to severe symptoms with active disease. Due to the many study options that we offer, the patient can either be biologic naïve OR needs to have failed traditional therapy (i.e. 6-Mp, Steroids, TNF-Inhibitors, etc.). The patient must be willing to undergo a colonoscopy as a study requirement. Clinical trial medications include oral agents, sub-cutaneous injectables, IV infusions, and more.
Ulcerative Colitis
We have multiple studies for ulcerative colitisfor patients between the ages of 18-75 years old. The potential patient needs to have moderate to severe symptoms with active disease. Due to the many study options that we offer, the patient can either be currently receiving treatment with Infliximab OR has loss of response to at least 1 conventional treatment (i.e. mesalamine, glucocorticoids, immunosuppressants, 6-mercaptopurine, methotrexate, anti-TNF, etc). Clinical trial medications include oral agents, sub-cutaneous injectables, IV infusions, and more.
